文献速递肝病

非酒精性脂肪性肝病纤维化分期的死亡率结局:系统评价与Meta分析

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-05-02

该系统评价与Meta分析纳入14篇文献共17301例经活检证实的非酒精性脂肪性肝病(NAFLD)患者,采用重建个体参与者数据和随机效应模型汇总生存数据。结果显示全因死亡率和肝相关死亡率随纤维化分期增加而显著升高,纤维化3-4期较0-2期全因死亡HR为3.32、肝相关死亡HR为10.40。

要点

  • 纤维化0-2期1年、5年、10年全因死亡率分别为0.1%、3.3%、7.7%,4期为0.3%、20.6%、41.5%。
  • 以纤维化0期为参照,2期、3期、4期全因死亡HR分别为1.46、1.96、3.66。
  • 以纤维化0期为参照,2期、3期、4期肝相关死亡HR分别为4.07、7.59、15.1。

核心结论

  • 全因死亡和肝相关死亡风险随纤维化分期增加而大幅升高,该数据对预后判断和试验设计有重要意义。

研究设计与样本

  • 系统评价与时间-事件Meta分析,检索Medline和Embase数据库,纳入报告经活检证实NAFLD按纤维化分期生存结局的队列研究,共14篇文章、17301例患者。

主要发现

  • 纤维化0-2期1年、5年、10年全因死亡率分别为0.1%、3.3%、7.7%,纤维化4期分别为0.3%、20.6%、41.5%。
  • 以纤维化0期为参照,全因死亡HR:2期1.46(95%CI 1.08-1.98),3期1.96(95%CI 1.41-2.72),4期3.66(95%CI 2.65-5.05)。
  • 以纤维化0期为参照,肝相关死亡HR:2期4.07(95%CI 1.44-11.5),3期7.59(95%CI 2.80-20.5),4期15.1(95%CI 5.27-43.4)。
  • 纤维化3-4期较0-2期全因死亡HR为3.32,肝相关死亡HR为10.40。
  • 纤维化4期较3期全因死亡HR为2.67(95%CI 1.47-4.83),肝相关死亡HR为2.57(95%CI 1.22-5.42)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty liver disease (NAFLD), but time-dependent risk of mortality has not been reported in previous meta-analyses. We performed an updated time-to-event meta-analysis to provide robust estimates for all-cause and liver-related mortality in biopsy-confirmed NAFLD with comparisons between fibrosis stages. METHODS: Medline and Embase databases were searched to include cohort studies reporting survival outcomes by fibrosis stage in biopsy-proven NAFLD. Survival estimates were pooled using reconstructed individual participant data. Conventional meta-analysis was conducted to pool adjusted hazard ratios (HRs) using DerSimonian and Laird random effects model. RESULTS: A total of 14 articles involving 17,301 patients with NAFLD were included. All-cause mortality at 1, 5, and 10 years for stage 0 to 2 fibrosis was 0.1%, 3.3%, and 7.7% vs 0.3%, 20.6%, and 41.5% for stage 4 fibrosis. Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08-1.98), stage 3; HR, 1.96 (95% CI, 1.41-2.72), and stage 4; HR, 3.66 (95% CI, 2.65-5.05). Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44-11.5), stage 3; HR, 7.59 (95% CI, 2.80-20.5), and stage 4; HR, 15.1 (95% CI, 5.27-43.4). Stage 3 to 4 fibrosis had a higher all-cause (HR, 3.32) and liver-related mortality (HR, 10.40) compared with stage 0 to 2 fibrosis, whereas stage 4 fibrosis had higher all-cause (HR, 2.67; 95% CI, 1.47-4.83) and liver-related mortality (HR, 2.57; 95% CI, 1.22-5.42) vs stage 3 fibrosis. CONCLUSIONS: Risk of all-cause and liver-related mortality increases substantially with fibrosis stage. These data have important implications for prognostication and trial design.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ng CH, Lim WH, Hui Lim GE, et al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022. PMID: 35513235. doi:10.1016/j.cgh.2022.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。